September 2005 Cover
|
 |
Incyte Corp.'s drug Reverset showed promise in reducing HIV in patients whose current regimens are not working, according to data the company presented at the 3rd International
AIDS Society Conference on HIV Pathogenesis and Treatment in Rio de Janeiro.
In a six-month trial involving 199 US and European patients, the greatest viral suppression in highly treatment-experienced patients was seen at the once-daily 200-mg Reverset
dose. The once-daily 50-mg and 100-mg dose levels were less effective. At least two cases of pancreatitis were found in patients taking the 200-mg dose in combination with didanosine
and tenofovir, but Incyte officials said didanosine has been historically associated with a risk of pancreatitis.
"At the 200-milligram dose, which is the highest dose tested in the study and the dose we plan to carry forward into Phase III [testing], the drug appears to have been very well
tolerated and to have substantial and significant antiviral potency," said researchers.
Editor's Note: from the Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
